🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#CVCT2024 Day 1 is on ! The brilliant Harriette Van Spall, MD MPH 🇨🇦 on Women as Trial Leaders, #WomeninTrials session ! #womenleaders Women As One

Join us for the joint NIH NHLBI CVCT - CardioVascular Clinical Trialists session on #ImplementationScience 8 am, Dec 10 With practical tips & cases that highlight how to design your trial to foster #implementation and how to translate research findings to clinical care. #CVCT24 #CVCT2024 #KT #TrialDesign

We need accelerated risk-based GDMT for CKD. #CVCT2024 CVCT - CardioVascular Clinical Trialists

Fantastic session on the implementation of the recent "explosion" of diabetes/CKD therapies Priorities of the panel: ✴️Use a risk-based approach ✴️Individualised approach to combination therapy ✴️Patient education ✴️Establishing CKD as a health priority #CVCT2024

Today, our 7⃣ Research Scholar Award winners joined with key faculty from CVCT - CardioVascular Clinical Trialists, Women As One, and industry leaders for a leadership lunch. Thank you to our sponsors, Abbott and Novo Nordisk US, for helping make this possible. #CVCT2024 #WIC

In the pipeline, VA-IMPACT trial is very interesting. Investigating Metformin in Prediabetes. #CVCT2024 CVCT - CardioVascular Clinical Trialists

Prof Will Herrington discusses the EMPA-KIDNEY trial on long-term effects of #empagliflozin in patients with #CKD. 📽️Watch here👉 ow.ly/f15x50UomXA #SGLT2 #CardioRenal #CVRM #CardioTwitter

🚨 OPEN CALL! 3 new YNP of ERA board members will be elected. Consider applying! Deadline: March 28, 2025

🎄 1/ New thread summarising the recently published NDT paper by YNP of ERA author Richard Shemilt 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Link to paper 👉academic.oup.com/ndt/article/39… 🧵by Kaitlin Mayne - this one is a particular privilege to feature since it is the work of many UofG SCMH colleagues🤩

EMPRESS-MI: Empagliflozin vs placebo, n=105 w/ LVSD (mean LVEF 34.8%) post-AMI (24wks): ↔️LVESVI, LVEDVI, LVEF, LAVI, LVMI ↔️NT-proBNP, hs-TnI ↗️Hct ↘️urate, weight 🔗 doi.org/10.1002/ejhf.3… Jaclyn Carberry Kieran Docherty Mark Petrie Colin Berry University of Glasgow Heart Failure Research Group UofG SCMH

🌟 Reflecting on a year of progress and achievement! Our 2024 Annual Report highlights our journey and the incredible women we support. Get insights into our programs, partnerships, and future goals. Explore the report now: linkedin.com/posts/women-as… #WIC #WomensHealth

🎉 We are thrilled to celebrate the YNP authors who successfully published as first, corresponding or last authors in NDT and CKJ in 2024! ERA - European Renal Association

We are pleased to announce the publication of the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Read the news release: kdigo.co/2025-ADPKD-Gui… This first-ever KDIGO guideline focused

Join NRS Renal Specialty and NRS_Diabetes on Thursday 1st May 2025 for our joint Research Day at Perth Concert Hall. Reserve a spot 👉tickettailor.com/events/nrstrau…

Systematic Review of the Effects of Iron on Cardiovascular, Kidney and Safety Outcomes in Patients With Chronic Kidney Disease - Kidney International Reports kireports.org/article/S2468-…

Editors’ Choice 2024: Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial This study's findings support the use of sodium-glucose cotransporter-2 inhibitors in CKD, irrespective of frailty, multimorbidity, or

🚨🚨🚨Excited to announce our Spring SpR Club meeting on Decisions in kidney transplantation 🫘 🫘 🫘 on 26-27 April taking place in York. Make sure you save your spot 🚨 🚨 🚨 gbr01.safelinks.protection.outlook.com/?url=https%3A%…

We're excited to be in York for our first joint collaborative event with Renal SpR Club talking all things kidney transplant this weekend Our kidney rep Kevin Breen adding to the Renal SpR Club welcome as we kick off 👋🏽